Drug Profile
PBI 05204 - Phoenix Biotechnology
Alternative Names: PBI-05204Latest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Phoenix Biotechnology; United States Army Medical Research Institute of Infectious Diseases; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Cardenolides
- Mechanism of Action Apoptosis stimulants; Fibroblast growth factor inhibitors; NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Transcription factor AP-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer
- Preclinical COVID 2019 infections; Viral infections
- No development reported Glioblastoma; Stroke
Most Recent Events
- 10 Aug 2023 Preclinical development is ongoing for Viral-infections in USA (PO)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Glioblastoma in USA (PO)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Glioblastoma presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)